Drug · Monoclonal Antibody
Zanidatamab
CI-DRUG-00000772Explore in graph →CHEMBL4650256 Approved
Regulatory
Approvals (7)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as ZIIHERA (DIN 02564610) under ATC L01FD07 ZANIDATAMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approved | — | health-canada-dpd |
| EU EMA | Malignant Biliary Tract Neoplasm | Ziihera as monotherapy is indicated for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC3+) biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy (for biomarker-based patient selection, see section 4.2).conditional | approved | Jun 27, 2025 | ema |
| US FDA | — | Efficacy supplement 2026-08-25 (see label) | approved | Aug 25, 2026 | openfda |
| US FDA | — | *This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 ) |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 18 hours agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 3 | 19 | 13 | 5 | 27 | 7 | CA, EU, US | Nov 20, 2024 | Mar 1, 2010 |
| Malignant Esophageal Neoplasm | Approved | Phase 3 | 3 | 2 | 1 | 3 | 2 | US | Nov 20, 2024 | Dec 2, 2021 |
| Malignant Breast Neoplasm | Phase3 | Phase 3 | 8 | 7 | 1 | 9 | 0 | — | — | Mar 1, 2010 |
| Malignant Gastric Neoplasm | Phase2 | Phase 2 | 3 | 2 | 0 | 4 | 0 |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (29)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07841873 | Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors(ZENITH-01) | not yet recruiting | Phase 2 | 15 | Anhui Provincial HospitalOTHER_GOV | 0 | Sep 25, 2026 | clinicaltrials |
| NCT04224272 | Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant |